Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

BACKGROUND: Vedolizumab (VDZ), a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative colitis (UC) patients. AIM: To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter co...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulusu, Samba Siva Reddy, Srinivasan, Ashish, Krishnaprasad, Krupa, Cheng, Daniel, Begun, Jakob, Keung, Charlotte, Van Langenberg, Daniel, Thin, Lena, Mogilevski, Tamara, De Cruz, Peter, Radford-Smith, Graham, Flanagan, Emma, Bell, Sally, Kashkooli, Soleiman, Sparrow, Miles, Ghaly, Simon, Bampton, Peter, Sawyer, Elise, Connor, Susan, Rizvi, Quart-ul-ain, Andrews, Jane M, Mahy, Gillian, Chivers, Paola, Travis, Simon, Lawrance, Ian Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438197/
https://www.ncbi.nlm.nih.gov/pubmed/32874055
http://dx.doi.org/10.3748/wjg.v26.i30.4428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438197/
https://www.ncbi.nlm.nih.gov/pubmed/32874055
http://dx.doi.org/10.3748/wjg.v26.i30.4428

Ejemplares similares